在Osteogenesis Imperfecta型V中的IFITM5突变与ERK/SOX9依赖的骨质生殖器分化缺陷有关
Ronit Marom1,2, I-Wen Song1, Emily C Busse1,3
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
The Journal of clinical investigation
|June 17, 2024
概括
骨质发育不完善型V是由IFITM5.5中的突变引起的. 这项研究表明,这种突变通过影响软骨细胞和信号通路,损害了骨发育.
科学领域:
- 骨生物学 骨生物学
- 遗传学 遗传学 是一个
- 发展生物学 发展生物学
背景情况:
- 骨质变生不完美 (OI) 型V是一种常见的OI形式,其特点是骨脆弱性,超塑性和化膜.
- 它是由干扰素诱导的跨膜蛋白5 (IFITM5) 基因中的特定的主导致病变体 (c.-14C>T) 引起的.
研究的目的:
- 通过使用条件Rosa26-knockin小鼠模型,研究复发的IFITM5突变的机械后果.
- 了解不同细胞类型中的突变IFITM5表达如何影响骨发育和平衡.
主要方法:
- 一个有条件的Rosa26-knockin小鼠模型的生成,表达突变Ifitm5.5.
- 分析骨表型,包括骨质,生长和内分泌骨骨化.
- 谱系追踪和分子分析以确定受影响的细胞群和信号通路 (ERK,SOX9).
主要成果:
- 突变的Ifitm5在骨质冠状腺细胞或冠状腺细胞中的表达导致了低骨质量,生长迟缓,内分泌骨化受损和生长板架构异常.
- 在成熟的骨质母细胞中,突变Ifitm5表达并没有导致显著的骨异常.
- 突变IFITM5激活了ERK信号传递和SOX9,破坏了骨质冠状元原生体分化和骨平衡.
结论:
- 这项研究确定了由于信号缺陷而导致的改变骨质冠状腺原生体差异化,作为Osteogenesis Imperfecta类型V病变发生的关键驱动因素.
- 抑制ERK和SOX9通路在突变动物中部分挽救了观察到的骨表型.
- 在骨架祖先中突变IFITM5的早期表达对OI类型V的发病过程至关重要.
相关概念视频
Bone Formation by Endochondral Ossification
4.3K
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
4.3K
Bone Formation by Intramembranous Ossification
5.9K
Intramembranous ossification is one of the two processes involved in the development of bones within an embryo. The flat bones of the face, most of the cranial bones, and the clavicles are formed via this process. During intramembranous ossification, the bones develop directly from sheets of undifferentiated mesenchymal connective tissue.
The process begins when mesenchymal cells in the embryonic skeleton gather together and differentiate into osteogenic cells, which then develop into ...
The process begins when mesenchymal cells in the embryonic skeleton gather together and differentiate into osteogenic cells, which then develop into ...
5.9K
Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
Pleiotropy
40.4K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
40.4K
Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K


